Skip to Content

Sanofi SA

Rating as of

Company Profile

Business Description

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just under 10% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of sales.

Contact
54, Rue La Boetie
Paris, 75008, France
T +33 153774000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Dec 31, 2019
Fiscal Year End Dec 31, 2020
Stock Type
Employees 100,409